Related Experiment Video
Updated: Jul 18, 2025

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
Ocular toxicity among patients taking anti-tubercular treatment
Sanjeeta Sitaula1, Ranju Kharel Sitaula, Shilu Thapa
1B.P. Koirala Lions Center for Ophthalmic Studies, Institute of Medicine, Maharajgunj Medical Campus, Maharajgunj, Kathmandu, Nepal.
Introduction:
Tuberculosis remains a major public health problem in Nepal and anti-tubercular drugs used for the treatment of pulmonary and extrapulmonary tuberculosis can be associated with ocular toxicity. This prospective study aimed to evaluate the incidence of ocular toxicity among patients receiving anti-tubercular therapy and to assess the change in visual functions and ocular imaging before and after use of anti-tubercular therapy.
Materials And Methods:
A total of 89 eyes of 45 TB patients taking anti-tubercular therapy were enrolled. Detailed history and examination including best-corrected visual acuity (BCVA), colour vision (Farnsworth D-15t), contrast sensitivity (Pelli-Robson chart), Goldman visual field analysis and spectral domain optical coherence tomography for retinal nerve fibre layer (RNFL) analysis were assessed at baseline and at 6 months after starting anti-tubercular therapy. Visual evoked potential (VEP) was performed in suspected cases.
Results:
The mean age of the patients was 29.13±14.00 years and 62.2% were males. The mean weight of the subjects was 54.37±10.36 kg, mean daily dosage of ethambutol was 17.91±1.74 mg/day/kg and mean administration duration was 2.71±1.54 months. The incidence of ocular toxicity was 2.24%. Bilateral retrobulbar optic neuropathy occurred in a 27-year female of 55 kg receiving ethambutol (20 mg/kg/day) for 6 months for Pott's spine. Her best-corrected visual acuity in both eyes was reduced to 6/36 from 6/6 and developed non-specific color vision defect, decreased contrast sensitivity, bilateral cecocentral visual field defect and mean decrease in retinal nerve fibre layer thickness compared to the baseline data. In rest cases, a statistically significant decrease in mean retinal nerve fibre layer thickness in both eyes suggested the evidence of subclinical toxicity.
Conclusion:
Though less common, ethambutol toxicity can occur in patients under anti-tubercular therapy in the form of retrobulbar optic neuritis. Decreased contrast sensitivity and thinning in the mean retinal nerve fibre layer thickness can be the indicator of subclinical toxicity.
Insights
Ocular toxicity from anti-tubercular drugs like ethambutol is rare but serious, potentially causing vision loss. Early signs include decreased contrast sensitivity and retinal nerve fibre layer thinning, indicating subclinical toxicity.
Area of Science:
- Ophthalmology
- Infectious Diseases
- Pharmacology
Background:
- Tuberculosis (TB) is a significant public health issue in Nepal.
- Anti-tubercular drugs can cause ocular toxicity.
- This study investigates ocular toxicity in TB patients undergoing therapy.
Purpose of the Study:
- To determine the incidence of ocular toxicity in patients on anti-tubercular therapy.
- To assess changes in visual function and ocular imaging before and after therapy.
Main Methods:
- Prospective study of 45 TB patients (89 eyes).
- Evaluated visual acuity, color vision, contrast sensitivity, visual fields, and retinal nerve fibre layer (RNFL) thickness via OCT.
- Visual evoked potential (VEP) used for suspected cases.
Main Results:
- Ocular toxicity incidence was 2.24%.
- One patient developed bilateral retrobulbar optic neuropathy with ethambutol.
- Subclinical toxicity indicated by decreased RNFL thickness in other patients.
Conclusions:
- Ethambutol toxicity, though uncommon, can manifest as retrobulbar optic neuritis.
- Decreased contrast sensitivity and RNFL thinning are indicators of subclinical ocular toxicity.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...

